Chronic Lymphocytic Leukaemia Clinical Trial
Official title:
A Retrospective Multicenter Trial on Efficacy and Toxicity of Bendamustine Alone or Associated With Rituximab, As Salvage Therapy in Patients With Chronic Lymphoproliferative Disorders
The purpose of this study is collect and evaluate the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.
All patients who meet the criteria for inclusion will be included in the study. A specific database will be created to collect the following information: personal data, medical history, histology related to the underlying disease, comorbidities, laboratory data, initial staging, data on the dosage and the number of cycles administered, the recorded toxicity data, the clinical response and the main events (relapse, progression, death, and cause of death). These data will then be retrospectively examined in order to obtain information about the life-saving treatment. ;
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03582098 -
Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
|
||
| Recruiting |
NCT06357754 -
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy
|
||
| Completed |
NCT02933320 -
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02267590 -
Tissue Collection for Biomarkers Determining Resistance to Ibrutinib
|
N/A | |
| Terminated |
NCT01127542 -
RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial
|
Phase 2 | |
| Recruiting |
NCT04763083 -
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
|
Phase 1 | |
| Completed |
NCT01597219 -
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers
|
Phase 2 | |
| Withdrawn |
NCT00504491 -
R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Terminated |
NCT01446900 -
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
|
Phase 2 | |
| Recruiting |
NCT01678430 -
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment
|
Phase 3 | |
| Terminated |
NCT00751296 -
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
|
Phase 2 | |
| Completed |
NCT01659255 -
Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL
|
Phase 1 | |
| Recruiting |
NCT04728893 -
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
|
Phase 2 | |
| Completed |
NCT01805375 -
A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
|
Phase 1 | |
| Completed |
NCT00457782 -
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Completed |
NCT00292760 -
A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion
|
Phase 2 |